23andMe cuts workforce by 40%, ends therapeutics division in drastic cost-saving measure
In a shocking turn of events, genetic testing powerhouse 23andMe announced it will slash 40% of its workforce, or roughly 200 employees, in a bid ... Read More
Tempus AI shakes up precision medicine with $600m acquisition of Ambry Genetics
Tempus AI has taken a significant step in advancing its precision medicine strategy by agreeing to acquire Ambry Genetics in a $600 million deal. This ... Read More
Discover the future of health: How 3X4 Genetics and Cenegenics are transforming wellness
In a significant move for the healthcare industry, 3X4 Genetics, a leader in genetic-based health testing, has announced a strategic partnership with Cenegenics, a top-tier ... Read More
Genetic Technologies unveils comprehensive genetic risk assessment test
Genetic Technologies Limited (GTG), a global leader in guideline-driven genomics-based testing for health, wellness, and serious diseases, has unveiled its most advanced risk assessment test ... Read More